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DNMT3A mutations mediate the epigenetic reactivation of the
leukemogenic factor MEIS1 in acute myeloid leukemia
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and M Esteller1,3,4
Close to half of de novo acute myeloid leukemia (AML) cases do not exhibit any cytogenetic aberrations. In this regard, distortion of
the DNA methylation setting and the presence of mutations in epigenetic modifier genes can also be molecular drivers of the
disease. In recent years, somatic missense mutations of the DNA methyltransferase 3A (DNMT3A) have been reported in ~ 20% of
AML patients; however, no obvious critical downstream gene has been identified that could explain the role of DNMT3A in the
natural history of AML. Herein, using whole-genome bisulfite sequencing and DNA methylation microarrays, we have identified a
key gene undergoing promoter hypomethylation-associated transcriptional reactivation in DNMT3 mutant patients, the
leukemogenic HOX cofactor MEIS1. Our results indicate that, in the absence of mixed lineage leukemia fusions, an alternative
pathway for engaging an oncogenic MEIS1-dependent transcriptional program can be mediated by DNMT3A mutations.
Oncogene (2016) 35, 3079–3082; doi:10.1038/onc.2015.359; published online 5 October 2015
INTRODUCTION
Acute myeloid leukemia (AML) comprises a group of hemato-
poietic malignancies derived from myeloid precursors that have a
highly heterogeneous clinical course and response to therapy.
AML is characterized by greater proliferation and lower differ-
entiation of the hematopoietic progenitor cells. Non-random
cytogenetic aberrations are the single most important prognostic
factor of the disease, but close to half of de novo AML cases do not
exhibit any.1 Many molecular drivers with potential prognostic
significance have been described particularly for this last group,
such as mutations in nucleophosmin, fms-related tyrosine kinase 3
and CCAAT/enhancer-binding protein-α. In recent years, distortion
of the DNA methylation setting and the presence of mutations in
epigenetic modifier genes, such as Tet methylcytosine dioxygen-
ase 2 and isocitrate dehydrogenase 1/2, have been directly
implicated in the pathogenesis of AML.2 In this regard, somatic
missense mutations of the DNA methyltransferase 3A (DNMT3A)
have also been reported in ~ 20% of AML patients, in whom they
are usually associated with an unfavorable prognosis.3–6
DNMT3A is a de novo DNA methyltransferase that catalyzes the
transfer of a methyl group onto the 5′-position of cytosine of CpG
dinucleotides. Most of the DNMT3A mutations present in AMLs are
heterozygous, with a great predominance of missense alterations
in the R882 residue located in the catalytic domain.3–6 R882H
DNMT3A has recently been shown to act as a dominant negative
that inhibits wild-type DNMT3A.7 In this context, AML samples
carrying DNMT3A mutations have been found to be associated
with DNA methylation changes.8,9 However, no clear and common
epigenetic signature has so far emerged and, most importantly, no
obvious critical downstream gene has been identified that could
explain the role of DNMT3A in the natural history of AML.
RESULTS AND DISCUSSION
To find downstream hypomethylated targets mediated by the
DNMT3A mutational event, we have taken an unbiased epigenetic
approach to examine the entire DNA methylome at the single-
nucleotide level of a well known DNMT3A AML mutant cell line
(OCI-AML3, which harbors a heterozygous R882C mutation)10 and
a widely used DNMT3A wild-type AML cell line (AML5). Using
whole-genome bisulfite sequencing (Supplementary Methods), we
generated 476 146 848 and 497 572 515 sequencing reads, of
which 74.3% (353 777 108) and 80.4% (400 048 302) mapped
uniquely to the human genome, respectively. Genome wide, we
achieved a base coverage of 23.1x for OCI-AML3 and 26.1x for
AML5 and 32.8x and 32.5x at CpG dinucleotides, respectively,
enabling us to interrogate DNA methylation levels for 425 M CpG
sites genome wide (45 reads per site). The complete whole-
genome bisulfite sequencing data from OCI-AML3 and AML5 are
illustrated in Figure 1a, and are available for download from NCBI
GEO (National Center for Biotechnology Information Gene
Expression Omnibus): http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?token=crcvqguqdhwxrsf&acc=GSE62303.
We observed that DNMT3A mutant AML cells had a 9% (66.1% vs
75.1%) decrease in average DNA methylation level and fewer
methylated CpG dinucleotides than did the DNMT3A wild-type cells
(Figures 1b and c). The diminished methylated CpG dinucleotide
content in OCI-AML3 observed with respect to AML5 cells is
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consistent with the reduced DNA methyltransferase activity
associated with the mutations described in DNMT3A.3–6 To find
specific target genes affected by the DNA hypomethylation events
noted in the AML cells harboring the DNMT3A mutation, we
searched for particular differentially methylated regions (DMRs)
between the two AML cell lines. These were defined as
consecutively and consistently differentially methylated loci located
beyond the 95% confidence interval (CI) of the smoothed
methylation profiles. Using these criteria, we identified 182 800
DMRs between OCI-AML3 and AML5 cells. The most common DMR
change was the presence of a methylated sequence in AML5 that
was unmethylated in OCI-AML3: 156 919 hypomethylated events
that represented 86% of the identified DMRs (Figure 1d). We
focused on those hypomethylated DMRs located in unique
candidate 5′-end regulatory promoters, which corresponded to a
total of 1416 genes. To identify the hypomethylated promoters that
had a transcriptional effect on the respective associated genes, we
complemented the whole-genome bisulfite sequencing data with
the results of an expression microarray experiment for the OCI-AML3
and AML5 cell lines (http://www.cancerrxgene.org/downloads/). This
approach yielded 292 genes with transcriptional activation asso-
ciated with promoter hypomethylation in DNMT3A mutant cells
relative to wild-type cells (Figure 1e and Supplementary Table S1).
We next examined how the profile of genes with
hypomethylation-associated expression derived from the
DNMT3A AML cell line models translated to primary samples
obtained from AML patients. To this end, we screened sixty-eight
AML patients (whose clinical information is summarized in
Supplementary Table S2) for DNMT3A mutations in exons 10–23
by direct Sanger sequencing; we also hybridized these samples to
a comprehensive DNA methylation microarray that interrogates
~ 450 000 CpG sites. We detected 14 DNMT3A mutations (21%) in
our AML group, a similar percentage to that reported previously,3–6
consisting of 13 R882 mutations (7 R882H, 4 R882S and 2 R882P)
and 1 S525C mutation. DNMT3A mutations were enriched in the
AML cases that showed no cytogenetic abnormalities (Fisher's exact
test, P=0.0353). None of our AML cases had mixed lineage
leukemia (MLL) translocations. AML patients with DNMT3A muta-
tions had a shorter 5-year overall survival (OS) (log-rank test;
P=0.046; hazard ratio, 95% CI: 2.02, 1.00–4.10).
When we combined the DNMT3A mutational status data with the
DNA methylation analysis of our 292 identified hypomethylated-
activated genes, we were able to define a signature of 12
hypomethylated gene promoters that were significantly enriched
in the primary AML cases carrying the DNMT3A mutations
(Wilcoxon's test; Po0.01) (Figure 2a and Supplementary Table S3).
Interestingly, this 12-gene hypomethylation signature was also
associated with worse OS (log-rank test; P=0.037; HR, 95% CI: 1.92,
1.03–3.60) (Figure 2a). The DNA hypomethylation signature of the 12
genes was validated in an independent cohort of primary AML
patient samples (n=194),2 in which the described hypomethylated
CpG sites were enriched in DNMT3A mutant patient samples
(Fisher’s exact test, Po0.01; Figure 2b). The 12-gene hypo-
methylated signature was also associated with shorter OS in
this validation group (log-rank test; P=0.014; HR, 95% CI: 1.89,
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Figure 1. Complete DNA methylomes of DNMT3A wild-type and mutant AML cell lines. (a) Global DNA methylation levels in the DNMT3A
mutant (OCI-AML3, outer circle) and wild-type (AML5, inner circle) cell lines analyzed by whole-genome bisulfite sequencing. Mean DNA
methylation levels are displayed for 10 Mb genomic segments and all chromosomes. (b) Genome-wide analysis of DNA methylation levels at
the CpG level (upper panel) and absolute number of hypermethylated (40.66 methylation level; lower panel) CpG dinucleotides. (c) Genome-
wide CpG methylation levels (upper panel) and DNA methylation profile exemplified by chromosome 1 (lower panel). (d) DNA methylation
levels in DMRs hypomethylated in AML3. (e) Difference in promoter methylation (x axis; OCI-AML3 vs AML5) is associated with differential
gene expression (y axis; OCI-AML3 vs AML5). Applied thresholds are indicated by dotted lines (δ DNA methylation 40.2; 1.5-fold change in
gene expression). The 292 identified hypomethylated and overexpressed genes are highlighted in purple (upper left quadrant).
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transcription–PCR that the hypomethylated status of these candidate
genes in the DNMT3A mutant OCI-AML3 cells was associated with a
high level of expression of the corresponding transcripts, whereas
their methylated status in DNMT3A wild-type AML5 cells was linked
to transcriptional repression (Figure 3a). These target genes include
two homeobox genes (HOXA11 and HOXB2), members of a family of
transcription factors involved in differentiation that, it has been
suggested, are hypomethylated in DNMT3A mutant AML.8,9
However, most importantly, the highest-ranked candidate gene,
whose five significantly differentially methylated CpG sites
spanned the largest region among the 12 genes (Supplementary
Table S3), was the leukemogenic HOX cofactor MEIS1. The
reactivation of the MEIS gene at the protein level in the DNMT3A
mutant cell line context was also confirmed (Figure 3b). The
targeting of of the DNMT3A protein to the MEIS gene was
observed using the chromatin immunoprecipitation assay
(Figure 3b). We also noted the impact of DNMT3A mutant-
mediated MEIS1 hypomethylation in the context of the primary
patient,2 whereby AML DNMT3A mutant patients were hypo-
methylated and had a higher level of expression of MEIS1
(Spearman's correlation; ρ=− 0.71, Po0.01) (Figure 3b). MEIS1 is
critical for the development of hematopoietic cells and has highly
regulated transcriptional activity with high levels observed in
hematopoietic stem cells and early progenitor cells, but down-
regulated expression in later stages of hematopoietic
development.11 This latter pattern appears to be disrupted in
leukemogenesis, as persistent overexpression of MEIS1 has been
consistently observed in association with poor prognosis in acute
leukemia patients.12 In addition, MEIS overexpression causes
shorter latency and accelerated progression in different leukemo-
genic models.13,14 Interestingly, the common translocations in
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Figure 2. DNMT3A mutations in AML are associated with a DNA hypomethylation signature characterized by poor patient survival and MEIS1
induction. (a) Hierarchical clustered DNA methylation levels (green: 0%; red: 100%) of 68 AML samples and 28 CpG sites significantly differentially
methylated between DNMT3A mutant (red) and wild-type patients (blue). The red boxes indicate samples assigned to the DNMT3A mutant-related
hypomethylated cluster. Differential survival analysis (5-year OS) of patients within (red line) or outside (blue line) the identified hypomethylated
cluster (n=64, right panel). (b) Hierarchical cluster of the 28 CpG sites related to DNMT3A mutation in 194 primary AML patient samples.2 The red
boxes indicate samples assigned to the DNMT3A mutant-related hypomethylated cluster. Differential survival analysis (5-year OS) of patients within
(red line) or outside (blue line) the identified hypomethylated cluster in the independent patient cohort (n=139, right panel).
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essential for the initiation and maintenance of MLL-rearranged
AML.13 In this regard, MEIS1 overexpression in murine bone
marrow progenitor generates an AML with features in common
with those driven by the MLL-fusion proteins.14
Our results suggest that, in the absence of MLL fusions, as in our
cases, an alternative pathway for engaging a leukemogenic MEIS1-
dependent transcriptional program can be mediated by DNMT3A
mutations. Under these circumstances, those AML patients carrying
the alteration in the DNA methyltransferase would undergo a
hypomethylation event at the MEIS1 promoter that would lead to
the overexpression of this key oncogene in leukemia.15
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Figure 3. DNMT3A mutations in AML are associated with a DNA
hypomethylation signature characterized by MEIS1 induction.
(a) DNA methylation level of the 28 CpG sites among the 12 candidate
genes in the OCI-AML3 and AML5 cell lines analyzed by DNA
methylation array (upper panel). Relative gene expression levels of
the 12 genes related to DNMT3Amutation profiled by quantitative PCR
in OCI-AML3 (black) and AML5 (gray) cell lines (lower panel). (b) Protein
levels of MEIS1 in OCI-AML3 and AML5 cells analyzed by immunoblot-
ting (top left panel). Quantitative chromatin immunoprecipitation assay
to assess DNMT3A occupancy at the MEIS1 studied CpG sites in AML5
cells. Data are presented as fold enrichment± s.e.m. Data of four
independent experiments are shown. Significance of Student’s t-tests is
shown. IgG, immunoglobulin G (top right panel). Standard deviations
are indicated by error bars. Bottom panel, association between the
DNMT3A mutation-related differentially methylated CpG sites in MEIS1
and transcriptional activity using matched data from 170 primary AML
samples (Cancer Genome Atlas Research Network2). Mean DNA
methylation levels over the five CpG sites of MEIS1 and gene
expression levels in DNMT3A mutant patients are shown.
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